质谱综述（英文）
The dramatically increased expenditures for both in-house
and outsourced pharmaceutical research and development
(R&D) have led to a greater dependence on technology.
New technologies are constantly introduced into drug
development to address throughput issues and improve
development cycles. The incorporation of new technologies
has resulted in fundamental change in the drug
development paradigm. Recently, sample generatingbased
technologies such as high throughput biomolecular
screening and automated parallel synthesis have shifted
the bottleneck to sample analysis-based technologies.
The current focus on analytical techniques in the
pharmaceutical industry emphasizes four primary figures
of merit: sensitivity; selectivity; speed; and high
throughput. Mass spectrometry (MS) provides each of
these key attributes, and therefore, has been benchmarked
an effective solution for pharmaceutical analysis in each
stage of drug development (1). Perhaps more enabling than
the MS-based technology itself is the diverse applications
of MS in conjunction with sample preparation, chromatographic
separation, and informatics. It is within this
context that MS has played an increasingly vital role in the
pharmaceutical industry and has become the preferred
½F1 analytical method for trace-mixture analysis (Fig. 1).
请点击此处下载
收藏
